Product and Procedure Advisories

This page will include position statements and other notifications from the College and other health organisations  concerning updates to expectations involving various medical products and procedures.  

CPSS Advisories and Position Statements

Angiotensin II Receptor Blockers (ARBs) (CPSS/SRNA/SCPP) (21/06)
Ketamine/Esketamine administered in any form IV/Oral/Sublingual/Intranasal as treatment for mental health and chronic non-cancer pain diagnoses (21/01)
PRP Advisory - Drug Panel Update (20/02)
Medical Assistance in Dying
Mifegymiso - Information for the Prescribing Physician (17/09, updated 17/11 and 19/04)
Stem Cell Therapies (19/05))
Platelet Rich Therapies (19/11)

Provincial/National Advisories/Policies

Viral Respiratory Testing & Outbreak Testing Update (SHA) (2022/01/19)
Discontinue of Helicobacter pylori Serology Testing (SHA) (2022/01/18)
Inclusion of Physician Address on all Requisitions - Requirement (SHA) (2022/01/18)
Amendment to the Controlled Drugs and Substances Act and the Narcotic Control Regulations (Tramadol) (2021/12)
Novel Coronavirus (COVID-19) - Information for Health Care Providers (SK Ministry of Health)
Drug and Vaccine Authorizations for COVID-19  (Health Canada portal)
Reporting of Deaths within 30 days of immunization as AEFIs (SK Ministry of Health) (2021/03)
2021 Tick Submissions for Identification and Testing Letter (2021/04) Poster

Please also be aware of the advisories and services by the following organisations:

Institute for Safe Medication Practices Canada (ISMP)

Safe Medication Use - Help Prevent Medication Errors (Health Canada) 
MedEffect Canada - Advisories and Recalls (Health Canada)
Health Product InfoWatch (Health Canada)
Canada Vigilance adverse reaction online database (Health Canada)
The Drug and Health Product Register - Summary Safety Reviews (Health Canada)